SCM
MRSN

Superstring Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Superstring Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,403
Closed -$221K – 40
2024
Q2 		$221K Buy
+4,403
New +$318K 0.28% 35

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Superstring Capital Management's MRSN Position: Q3 2024 in Review

Superstring Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2024, closing a stake of 4,403 shares — an estimated $221K sold.

Superstring Capital Management first reported a position in MRSN in Q2 2024 and held it in 1 quarter. The position peaked at $221K in Q2 2024. 113 funds tracked by Wall St. Rank hold MRSN as of Q3 2024.

  • Superstring Capital Management reported no remaining Mersana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Superstring Capital Management sold 4,403 Mersana Therapeutics shares in Q3 2024, an estimated $221K.
  • Superstring Capital Management first reported a position in Mersana Therapeutics in Q2 2024 and held it in 1 quarter.
  • Superstring Capital Management's Mersana Therapeutics position peaked at $221K in Q2 2024.
  • 113 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2024.

Based on Superstring Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.